Plasma levels of soluble tumor necrosis factor receptors are associated with cognitive performance in Parkinson's disease

Movement Disorders

Volumn 29, Issue 4, 2014, Pages 527-531

  Rocha, Natália Pessoa ^a   Teixeira, Antônio Lúcio ^a   Scalzo, Paula Luciana ^a   Barbosa, Izabela Guimarães ^a   de Sousa, Mariana Soares ^b   Morato, Isabela Boechat ^a   Vieira, Érica Leandro Marciano ^a   Christo, Paulo Pereira ^b   Palotás, András ^c   Reis, Helton José ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b Hospital Santa Casa de Belo Horizonte   (Brazil)

^c Asklepios Med (private medical practice and research center)   (Hungary)

Author keywords

Cognition; Inflammation; Non motor symptoms; Parkinson's disease; Tumor necrosis factor

Indexed keywords

BIOLOGICAL MARKER; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1;

AGED; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; EDUCATION; EXECUTIVE FUNCTION; FEMALE; FRONTAL ASSESSMENT BATTERY; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOMETRY; SCORING SYSTEM; BLOOD; COGNITION DISORDERS; COMPLICATION; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PHYSIOLOGY; PSYCHOLOGY;

AGED; BIOLOGICAL MARKERS; COGNITION; COGNITION DISORDERS; EXECUTIVE FUNCTION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 84898058393     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25752     Document Type: Article

References (26)

1. Aarsland D, Påhlhagen S, Ballard CG, Ehrt U, Svenningsson P. Depression in Parkinson disease-epidemiology, mechanisms and management. Nat Rev Neurol 2011;8:35-47.
2. Bugalho P, Vale J. Brief cognitive assessment in the early stages of Parkinson disease. Cogn Behav Neurol 2011;24:169-173.
3. Kummer A, Teixeira AL. Neuropsychiatry of Parkinson's disease. Arq Neuropsiquiatr 2009;67(3B):930-939.
4. Diniz BS, Teixeira AL, Ojopi EB, et al. Higher serum sTNFR1 level predicts conversion from mild cognitive impairment to Alzheimer's disease. J Alzheimers Dis 2010;22:1305-1311.
5. Barbosa IG, Rocha NP, Huguet RB, et al. Executive dysfunction in euthymic bipolar disorder patients and its association with plasma biomarkers. J Affect Disord 2012;137(1-3):151-155.
6. Phani S, Loike JD, Przedborski S. Neurodegeneration and inflammation in Parkinson's disease. Parkinsonism Relat Disord 2012;18(Suppl 1):S207-S209.
7. Tracey KJ, Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med 1994;45:491-503.
8. Aderka D. The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Cytokine Growth Factor Rev 1996;7:231-240.
9. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
10. Fahn S, Elton R. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Caine DB, Goldstein M, eds. Recent Developments in Parkinson's Disease. Vol 2. Florham Park, NJ: Macmillan Health Care Information; 1987:153-163.
11. Höhn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
12. Folstein MF, Folstein SE, Mchugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
13. Brucki SM, Nitrini R, Caramelli P, Bertolucci PH, Okamoto IH. Suggestions for utilization of the mini-mental state examination in Brazil. Arq Neuropsiquiatr 2003;61:777-781.
14. Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a frontal assessment battery at bedside. Neurology 2000;55:1621-1626.
15. Beato RG, Nitrini R, Formigoni AP, Caramelli P. Brazilian version of the Frontal Assessment Battery (FAB): preliminary data of administration to healthy elderly. Dement Neuropsychol 2007;1:59-65.
16. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Psychiatry 1961;4:561-571.
17. Silberman CD, Laks J, Capitão CF, Rodrigues CS, Moreira I, Engelhardt E. Recognizing depression in patients with Parkinson's disease: accuracy and specificity of two depression rating scale. Arq Neuropsiquiatr 2006;64:407-411.
18. Tumas V, Rodrigues GG, Farias TL, Crippa JA. The accuracy of diagnosis of major depression in patients with Parkinson's disease: a comparative study among the UPDRS, the geriatric depression scale and the Beck depression inventory. Arq Neuropsiquiatr 2008;66:152-156.
19. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 1994;165(1-2):208-210.
20. Boka G, Anglade P, Wallach D, Javoy-Agid F, Agid Y, Hirsch EC. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci Lett 1994;172(1-2):151-154.
21. Brodacki B, Staszewski J, Toczyłowska B, et al. Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFalpha, and INFgamma concentrations are elevated in patients with atypical and idiopathic parkinsonism. Neurosci Lett 2008;441:158-162.
22. Reale M, Iarlori C, Thomas A, et al. Peripheral cytokines profile in Parkinson's disease. Brain Behav Immun 2009;23:55-63.
23. Katsarou Z, Bostantjopoulou S, Hatzizisi O, Giza E, Soler-Cardona A, Kyriazis G. Immune factors or depression? Fatigue correlates in Parkinson's disease. Rev Neurol 2007;45:725-728.
24. Scalzo P, Kümmer A, Cardoso F, Teixeira AL. Increased serum levels of soluble tumor necrosis factor-alpha receptor-1 in patients with Parkinson's disease. J Neuroimmunol 2009;216(1-2):122-125.
25. Hasegawa Y, Inagaki T, Sawada M, Suzumura A. Impaired cytokine production by peripheral blood mononuclear cells and monocytes/macrophages in Parkinson's disease. Acta Neurol Scand 2000;101:159-164.
26. Menza M, Dobkin RD, Marin H, et al. The role of inflammatory cytokines in cognition and other non-motor symptoms of Parkinson's disease. Psychosomatics 2010;51:474-479.